Artificial intelligence (AI) platforms are making substantial strides in drug discovery and clinical decision-making. The UK-based startup OutSee released Nomaly, an AI model that predicts phenotypes and underlying biological mechanisms from protein domain variants, facilitating novel therapeutic target identification. Separately, Novartis forged a multimillion-dollar collaboration with ProFound Therapeutics to leverage proteomic and computational capabilities to explore unexplored protein targets for cardiovascular disease. These developments underscore AI's growing role in accelerating drug discovery pipelines and optimizing disease treatment strategies.